Information Provided By: 
Fly News Breaks for August 6, 2019
PODD
Aug 6, 2019 | 07:59 EDT
Jefferies analyst Raj Denhoy raised his price target for Insulet to $140 from $105 saying Omnipod adoption "remains hot" following the company's better than expected Q2 results. The launch of Dash, the accompanying move to pharmacy benefit, and the general adoption of technology broadly in diabetes continue to spur growth, Denhoy tells investors in a research note. The analyst raised his estimates and keeps a Buy rating on Insulet.
News For PODD From the Last 2 Days
There are no results for your query PODD
